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Abstract
Constipation is a common problem and its prevalence increases with age. Severe constipation requires
treatment with laxatives, but nutritional therapy, especially increased dietary fibre intake, is recommended
primarily for the prevention and treatment of mild constipation. One alternative may be the use of
oligosaccharides, which act as soluble fibre and have a bifidogenic effect. Galacto-oligosaccharides (GOS)
resembling oligosaccharides occurring naturally in human milk can be produced from lactose. Several clinical
studies reviewed in this paper have shown that the use of GOS (515 g per day) may relieve the symptoms of
constipation in adults and elderly people. In infants, the supplementation of formula with a mixture of GOS
and fructo-oligosaccharides can modulate bowel function and stool characters in the same direction as does
breast-feeding. Gastrointestinal symptoms may occur as side-effects of oligosaccharides, but 12 g GOS per
day or less is usually well tolerated.
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Introduction
C
onstipation is a common problem that re-
duces the quality of life. The estimated
prevalence of constipation varies from 2 to
27% (1), and the number of people reporting
constipation increases with age (2). Diet and life-
style are factors that affect bowel function, and
adequate intakes of dietary fibre and fluid are
usually recommended for the prevention of con-
stipation. Serious constipation requires treatment
with laxatives. Bulk laxatives, which absorb water
from the intestinal lumen and soften stool, are
generally well tolerated, but gas production and
bloating may occur. Stimulant laxatives, which
increase intestinal motility and secretion of water
to the lumen, are more effective than bulk laxatives.
However, unwanted effects such as abdominal
cramps and, in chronic treatment, the development
of gastrointestinal tolerance may result from the use
of stimulant laxatives (3).
An alternative among nutritional therapies for
constipation is the use of prebiotics, includ-
ing galacto-oligosaccharides (GOS) and fructo-
oligosaccharides (FOS). The latter occur naturally
in vegetables and can be commercially produced
from sucrose or through hydrolysis of chicory roots.
GOS is a collective term for a group of carbohy-
drates composed of oligo-galactose with some
lactose and glucose. They are produced commer-
cially from lactose by b-galactosidase (4). Oligosac-
charides resembling GOS occur naturally in human
milk and may be one of the factors that protect
human infants from gastrointestinal pathogenic
bacteria (5). In the literature the terms trans-
oligosaccharide (TOS) and trans-galacto-oligosac-
charide (TGOS) occur as synonyms for GOS. In this
paper, the term GOS is used since it appears to be
the most frequently used term.
The laxative effects of prebiotics such as GOS
and FOS are attributed to their action as soluble
fibres. They pass undigested into the colon where
bacteria hydrolyse and ferment them (6). In addi-
tion, several studies on both infants (5, 7, 8) and
adults (911) have shown the prebiotic, bifidogenic
effect of GOS or a mixture of GOS and FOS on
colonic flora. Some researchers have suggested that
a reduction in the number of bifidobacteria has
been related to constipation, and treatment to
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correct this could therefore benefit bowel function
(12).
This review summarizes clinical data concerning
the effect of GOS on bowel function. To identify
human clinical trials eligible for the review a Med-
line search was conducted, and publications on
GOS and bowel function were included. Additional
studies were obtained from the references of the
selected articles, and from other databases and
sources, and they were included if they were written
in English or had an English abstract.
Effects of galacto-oligosaccharides on bowel
function
Several studies performed in the elderly (1315) and
in adults (9, 1619) have examined the laxative
effect of GOS. In addition, several clinical trials
have examined the effects of a mixture of GOS and
FOS on bowel function in infants (5).
Studies in the elderly
Constipation is not a physiological consequence of
ageing. However, age-related changes, such as
increased use of medications, dietary changes and
decreased mobility, may contribute to the increased
prevalence of constipation in older adults. When the
intake of food decreases with age, the intake of fibre
may be inadequate to prevent constipation (20). The
use of GOS offers an alternative to increase the
amount of indigestible carbohydrates, i.e. dietary
fibre, in the diet.
The composition of faecal flora changes with age,
and in comparison to young adults, the number of
bifidobacteria may decline in healthy elderly people
(21, 22). These changes may alter intestinal motility,
and thus treatment increasing bifidobacteria may
relieve symptoms of constipation (12). Narimiya et
al. (13) studied the effects of GOS (18.5 g per day),
used as a substitute for sugar, on bowel function
and faecal flora in 12 elderly subjects (mean age
66 years) suffering from type 2 (non-insulin-depen-
dent) diabetes. Nine subjects were constipated and
three had normal bowel function. In 11 subjects
faeces were softer during the 1 month GOS period
than during the baseline. In five subjects the laxative
effect of GOS was statistically significant and
accompanied by an increase in the ratio of bifido-
bacteria to total bacteria.
Teuri and Korpela (14) investigated the laxative
effects of GOS in 14 elderly subjects (mean age
80 years) suffering from constipation. The study
was a double-blind, two-period cross-over study
lasting for 6 weeks. After a 1 week run-in period,
the subjects ingested, in random order, either a GOS
yoghurt (9 g of GOS per day) or a placebo yoghurt
twice daily for 2 weeks. Faecal samples were col-
lected from nine volunteers during the run-in period
and at the end of the study periods. The weekly
defecation frequency was higher during the GOS
period (mean 7.1, range 315) than during the
control period (mean 5.9, range 114).
Recently, Sairanen et al. (15) examined the effect
of yoghurt containing GOS (12 g per day), prunes
(12 g per day) and linseed (6 g per day) on bowel
function in 43 constipated, free-living elderly sub-
jects (mean age 76 years). In this double-blind cross-
over study, the subjects consumed, in random order,
260 g per day of either test yoghurt or control
yoghurt for 3 weeks. This study showed the effects
of the yoghurt containing GOS, prunes and linseed.
The defecation frequency was higher (8.0 versus
7.1 times per week, p0.01) and defecation easier
(p0.01). However, effects of the different fibre
sources could not be separated in this study.
It has been reported that 65% of elderly people
reporting constipation defecate at least once daily,
and constipation among the elderly usually means
difficulty in evacuation and hard stools (23). The
results of the studies investigating the laxative effect
of GOS in elderly people indicate that GOS reduce
the most common symptoms of constipation in the
elderly. The use of GOS could not, however, totally
replace other laxatives (14, 15).
Studies in adults
The laxative effect of GOS varies from patient to
patient (15, 16), as does the effect of any other fibre
(24). Deguchi et al. (16) examined the laxative effect
of GOS in 128 healthy adults with constipation
tendency in two single-blind, placebo-controlled
trials. In the first study, 76 women ingested a
beverage supplemented with GOS (2.5 or 5 g per
day) or a placebo beverage for 1 week. After a
1 week washout period, the subjects were inverted
for the second 1 week intervention period. In the
second trial, 50 volunteers ingested daily a placebo
beverage during the first 1 week intervention period
and a beverage supplemented daily with 10 g of
GOS during the second 1 week intervention period.
After ingesting 5 or 10 g of GOS daily, defecation
frequency increased from 0.92 to 1.07 (pB0.05)
and from 0.85 to 0.97 (pB0.05) times per day,
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respectively, and faeces became softer (pB0.05).
The laxative effect of GOS was more marked in
those with low defecation frequency.
The results of studies investigating the laxative
effects of GOS in adults with normal bowel habits
are contradictory. Teuri et al. (17) investigated
the effects of yoghurt supplemented with 15 g
of GOS daily in 12 healthy volunteers. The
median frequency of defecation increased (pB0.05,
Friedman’s ANOVA) from eight times per week
during the 1 week control period to nine and 10
times per week during the first and second admin-
istration weeks, respectively. The number of faecal
bifidobacteria, analysed from six volunteers,
showed no change, but the growth of bacteria on
Lactobacillus-selective agar (MRS) increased (pB
0.05). Ito et al. (9) investigated the effects of an
apple juice supplemented with GOS in a single-blind
study. During four 1 week intervention periods, 12
healthy adults ingested 0, 2.5, 5 and 10 g of GOS
daily according to a Latin square design. One-week
washout periods separated the intervention periods.
In this study, stool frequency showed no significant
change after the ingestion of GOS, but the number
of bifidobacteria increased and the stools softened.
Van Dokkum et al. (18) examined the effects of an
orange juice supplemented with indigestible oligo-
saccharides in a randomized, double-blind, Latin
square study. Ingestion of GOS (15 g per day) for
3 weeks did not affect stool frequency in 12 healthy
volunteers, but a significantly lower percentage of
faecal dry weight was measured during the GOS
period than during the placebo period. In contrast,
Alles et al. (19) reported that ingestion of GOS (7 or
15 g per day) for 3 weeks did not significantly affect
bowel habits or stool composition in adults with
normal bowel function. It seems that in adults with
normal bowel function, the effects of GOS are less
clearcut.
Studies in infants
Intestinal microbiota plays an important role in the
postnatal development of gastrointestinal functions.
Several clinical trials have shown that the supple-
mentation of infant formula with a mixture of GOS
and FOS benefits bowel function in both preterm
and term infants; these data were summarized in a
recent review by Fanaro et al. (5). Thus, infant
formula supplemented with a mixture of GOS and
FOS stimulated the growth of intestinal bifidobac-
teria and lactobacilli in infants. In addition, the
supplementation of infant formula with GOS and
FOS has modified stool consistency and increased
defecation frequency to levels similar to those found
in breastfed infants. In these studies, mixtures of
GOS and FOS (GOS 90%, FOS 10%) resembling
human milk oligosaccharides have been used (5),
and it is impossible to separate the individual effects
of the oligosaccharides (25). However, because the
prebiotic mixtures contained mainly GOS, these
studies provide supportive evidence of the benefits
of GOS on bowel function.
Possible adverse effects of galacto-
oligosaccharides
The bacterial fermentation of undigested carbohy-
drates increases the production of gases in the colon
(26) and may cause adverse gastrointestinal symp-
toms such as flatulence, which are common side-
effects of increasing fibre intake (24). Because GOS
are fermented in the colon, gastrointestinal symp-
toms may occur after their ingestion (16, 17).
Usually, tolerance to fibre depends on the amount
of the product eaten (27). Similarly, the frequency of
gastrointestinal symptoms increases when the dose
of GOS increases (9, 16). In most of the studies,
amounts of 12 g of GOS or less daily were well
tolerated (14, 15), but 15 g of GOS per day
increased flatulence (17). However, individuals
vary considerably in their response to GOS (15),
as with their response to any other easily fermented
fibre (27).
Mechanisms behind the laxative effect
The laxative effect of GOS is believed to be caused
by its action as a soluble fibre. Oligosaccharides
pass undigested into the large intestine and stimu-
late bacterial fermentation in the colon. The bacter-
ial fermentation of oligosaccharides increases
bacterial mass, which in turn increases faecal bulk.
Undigested oligosaccharides and fermentation pro-
ducts may also produce an osmotic effect in the gut,
which increases the water content of faeces (28). The
increased bowel content stimulates peristalsis in the
colon (26). However, studies so far with 10 g (9) or
15 g (19) have been unable to demonstrate any
significant effect of GOS on stool weight.
In addition, GOS may alter bowel function
through a change in the colonic environment. In
vitro studies have shown that the bacterial fermen-
tation of oligosaccharides increases the production
of short-chain fatty acids (SCFAs) (11, 29), which
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lowers colonic pH (28). The lower colonic pH may
stimulate the growth of lactobacilli and bifidobac-
teria and suppress the growth of undesirable
bacteria (29). SCFAs may also affect intestinal
motility, but the clinical relevance and mechanisms
of this action remain uncertain (30). In humans, the
results of the studies examining the effects of GOS
on the concentration of SCFAs in the faeces are
contradictory (18, 19). It should be noted that the
increase in the production of SCFAs in the colon is
difficult to determine in humans, because SCFAs
are rapidly absorbed in the gut, and thus the
amount of SCFAs in the faeces does not necessarily
correspond to their intracolonic production (11).
Conclusions
Several clinical trials have shown that the use of
GOS may reduce the severity of mild constipation.
In constipated people, the ingestion of GOS has
softened stools, increased defecation frequency and
facilitated defecation. The laxative effect of GOS is
more marked in people with low defecation fre-
quency, and in adults with normal bowel function
the effects of GOS may be limited. In infants, the
supplementation of formula with a prebiotic mix-
ture of GOS/FOS can modulate bowel function and
stool characters in the same direction as does
breast-feeding. Gastrointestinal symptoms, which
are common side-effects of all fibre, may occur after
the ingestion of GOS. However, amounts of 12 g or
less daily are usually well tolerated. The bulking
capacity of GOS remains to be clarified in future
studies.
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